Literature DB >> 6280473

Angiotensin-converting enzyme inhibition and prostaglandins.

S L Swartz, G H Williams.   

Abstract

To determine whether prostaglandins contribute to the depressor response of angiotensin-converting enzyme inhibitors, plasma prostaglandin levels were measured by radioimmunoassay in normo- and hypertensive subjects on both sodium-restricted and sodium-loaded diets before and after captopril administration. On the sodium-restricted diet, the hypotensive response to captopril was accompanied by significant increments in the metabolite of prostaglandin E2 (PGE2-M) and bradykinin and by significant decrements in angiotensin II. The high sodium diet suppressed the response of the renin-angiotensin and kinin systems to captopril but the hypotensive response persisted. Furthermore, the decrease in blood pressure correlated significantly with increments in prostaglandin E2-metabolite. Prostaglandin synthesis was then inhibited in the sodium-restricted hypertensive patients by pretreatment with indomethacin. This maneuver completely eliminated the captopril-induced prostaglandin E2-metabolite increment without changing bradykinin or angiotensin II responses but significantly attenuating the hypotensive response. Finally, when patients were studied on a high sodium intake, similar effects were observed except now indomethacin completely abolished the blood pressure response to captopril. These studies therefore support the hypothesis that increased production of vasodilator prostaglandins in a major mediator of the hypotensive response to captopril. Whether the change in prostaglandin release is a direct effect of the drug or secondary to increased kinin levels is uncertain.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6280473     DOI: 10.1016/0002-9149(82)90351-4

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  26 in total

1.  The effect of captopril on peripheral hemodynamics in patients with essential hypertension: comparison between oral and sublingual administration.

Authors:  C Longhini; L Ansani; G Musacci; D Mele; M Vaccari; E Baracca; P Sgobino
Journal:  Cardiovasc Drugs Ther       Date:  1990-06       Impact factor: 3.727

2.  Hemodynamic effects of benazepril, an angiotensin-converting enzyme inhibitor, as studied in conscious normotensive dogs.

Authors:  T Ishibashi; S Tatebe; A Mitomi; M Tanaka; S Imai
Journal:  Cardiovasc Drugs Ther       Date:  1991-06       Impact factor: 3.727

3.  Cough due to captopril.

Authors:  E M McNally
Journal:  West J Med       Date:  1987-02

Review 4.  Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  R N Brogden; P A Todd; E M Sorkin
Journal:  Drugs       Date:  1988-11       Impact factor: 9.546

Review 5.  Angiotensin converting enzyme inhibitors and moderate hypertension.

Authors:  D McAreavey; J I Robertson
Journal:  Drugs       Date:  1990-09       Impact factor: 9.546

6.  Coronary vasodilation induced by captopril and zofenoprilat: evidence for a prostaglandin-independent mechanism.

Authors:  J van Wijngaarden; R A Tio; W H van Gilst; P A de Graeff; C D de Langen; H Wesseling
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-05       Impact factor: 3.000

7.  A comparison of the effects of captopril and enalapril on skin responses to intradermal bradykinin and skin blood flow in the human forearm.

Authors:  T C Li Kam Wa; E D Cooke; P Turner
Journal:  Br J Clin Pharmacol       Date:  1993-01       Impact factor: 4.335

8.  Effect of enalapril on allergen-induced cutaneous hypersensitivity reaction.

Authors:  J R Snyman; D K Sommers
Journal:  Br J Clin Pharmacol       Date:  1991-12       Impact factor: 4.335

Review 9.  Angiotensin converting enzyme inhibitors: comparative structure, pharmacokinetics, and pharmacodynamics.

Authors:  G S Thind
Journal:  Cardiovasc Drugs Ther       Date:  1990-02       Impact factor: 3.727

Review 10.  Adverse effects of angiotensin converting enzyme (ACE) inhibitors. An update.

Authors:  R C Parish; L J Miller
Journal:  Drug Saf       Date:  1992 Jan-Feb       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.